Recent Company News

• 05:14 PM ET May 02, 2025
  

  I-Mab files $250M mixed shelf; enters ADS sales agreement for up to $21M with LeerinkPartners - F-3 ($0.95, 0.00)

• 03:45 PM ET Apr 10, 2025
  

  Trump administration moving forward with potential delisting of Chinese stocks on US exchanges -- FBN's Gasparino

• 04:05 PM ET Apr 03, 2025
  

  I-Mab reports FY net income from cont ops ($49.7M) vs year-ago ($82.2M) ($0.73, 0.00)

• 07:02 AM ET Mar 07, 2025
  

  I-Mab announces accelerated Givastomig phase 1B study progress ($0.87, 0.00)

• 07:14 AM ET Jan 29, 2025
  

  I-Mab completes ~27% workforce reduction - 6-K ($1.03, 0.00)

• 07:51 AM ET Jan 13, 2025
  

  I-Mab provides anticipated upcoming milestones - slides - 6-K ($1.05, 0.00)

• 07:10 AM ET Jan 08, 2025
  

  I-Mab chairman Wei Fu plans to purchase up to $2M of company ADSs in open market - 6-K ($0.98, 0.00)

• 07:05 AM ET Jan 06, 2025
  

  I-Mab announces portfolio prioritization of givastomig as lead clinical program ($0.94, 0.00)

• 07:09 AM ET Nov 14, 2024
  

  I-Mab reports Q3 non-GAAP EPADS ($0.25) vs year-ago ($0.39) ($1.04, 0.00)

• 07:13 AM ET Nov 06, 2024
  

  I-Mab appoints Sean Fu, PhD, MBA, as CEO ($1.13, 0.00)